Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MR Image Quality and Liver Lesion Detection with Gadopiclenol: Comparison with Gadoxetate Disodium

Trial Status: active

This study compares the image quality and liver lesion detection of using a recently FDA (food and drug administration) approved gadolinium-based contrast agent (GBCA) for magnetic resonance imaging (MRI) called gadopiclenol (Elucirem™) compared to a routinely used gadolinium-based contrast agent (gadoxetate disodium, Eovist™/Primovist™ Bayer Healthcare) for MRI exam of the liver in patients undergoing clinically indicated liver imaging. MRI uses magnetic waves to look at soft tissues in the body.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.